This study is for patients that have been diagnosed with multiple myeloma. The investigational drugs in this study are lenalidomide and daratumumab. The purpose of this study is to compare overall survival between the two treatment arms with lenalidomide as the comparator arm and lenalidomide + daratumumab/rHuPH20 as the experimental arm in post-autologous transplant multiple myeloma patients. Participants can expect to be on this study for up to 7 years. After 7 years, participants may be followed by telephone for up to 15 years from the time they started study treatment.

This study is for patients that have been diagnosed with smoldering multiple myeloma (SMM). The drugs used in this study are daratumumab, lenalidomide and dexamethasone which are all commercially used drugs. The purpose of this study is to compare overall survival in patients with high-risk smoldering multiple myeloma randomized to daratumumab revlimid-dexamethasone or revlimid-dexamethasone. Participants can expect to be on this study for up to two years and followed by your doctor for up to 15 years.

This study is for patients that have been diagnosed with amyloid light chain (AL) amyloidosis. The Investigational drug in this study is isatuximab. The purpose of this research is to assess the efficacy as measured by the confirmed overall hematologic response rate (partial response or better) of isatuximab in relapsed/ refractory systemic light chain (AL) amyloidosis. Participants can expect to be on this study for up to 2 years and followed for up to 2 additional years after study drug completion.